Learning Objectives:  Chablani

1. Review current first-line treatment options for metastatic urothelial cancer

2. Provide an overview of how antibody drug conjugates work and benefits/shortcomings

3.  Discuss the phase II study that led to the FDA approval of Enfortumab Vedotin in Dec 2019 for metastatic urothelial cancer

..

Learning Objectives:  Hawking 

1.  To learn about the history of the medical futility debate.

2.  To develop a framework for thinking through futile cases and approaching families

3.

Session date: 
Monday, June 29, 2020 - 12:00pm to 1:00pm
Speaker Name: 
Priyanka Chablani, MD & Michael Hawking, MD, MSc
Location: 
UCMC
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.